Therapeutics/Diagnostics News

VANCOUVER, British Columbia — Results from a systematic review and network meta-analysis showed 10 interventions, including dual observation, iScan and G-EYE, improved adenoma detection rate during screening-related colonoscopy.

VANCOUVER, British Columbia — A digital risk assessment tool and genetic testing program can be helpful in identifying patients with high-risk cancer susceptibility syndromes, according to a presenter at the ACG Annual Scientific Meeting.

VANCOUVER, British Columbia — Mechanical-enhanced colonoscopy outperformed standard colonoscopy in polyp detection rate and estimated adenoma detection rate for colorectal cancer screening, according to a presenter here.

The FDA has approved Phathom Pharmaceuticals’ Voquezna tablets 10 mg and 20 mg to treat erosive esophagitis, or erosive gastroesophageal reflux disease, and alleviate heartburn associated with the disease, noted a company release.

VANCOUVER, British Columbia — Predictors of sessile serrated lesions among veterans who underwent colonoscopy within 12 months of a positive fecal immunochemical test included older age, obesity and smoking, according to a presenter.

VANCOUVER, British Columbia — A post hoc analysis of the ELEVATE UC trials demonstrated “rapid treatment effect” with early symptomatic response among patients treated with etrasimod for ulcerative colitis, according to a presenter.

The FDA has approved Eli Lilly’s Omvoh infusion/injection as the “first and only” interleukin-23p19 antagonist for the treatment of patients with moderately to severely active ulcerative colitis, according to a company release.

VANCOUVER, British Columbia — In this Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, discusses the evolution of treatment for Clostridioides difficile infection, from antimicrobials to recently FDA-approved live biotherapeutics.

VANCOUVER, British Columbia — In a Healio video exclusive, Edward V. Loftus Jr., MD, FACG, discusses results from the INSPIRE trial, in which more patients with ulcerative colitis achieved clinical remission on IV risankizumab vs. placebo.

VANCOUVER, British Columbia — A next-generation, multitarget stool DNA test detected colorectal cancer with 94% sensitivity and 91% specificity, outperforming fecal immunochemical testing, according to late-breaking data here.